



**July 29, 2021**

**To,  
Dept of Corporate Services,  
BSE Limited,  
PJ Towers, Dalal Street,  
Fort, Mumbai-400001**

**Sub:** Intimation GLP re-certification in Vanta Bioscience Limited and commencement of commercial operations in Vayam Research Solutions Limited

**Ref:** Reg 30 of SEBI (LODR) Regulations, 2015

**GLP Re-certification and Scope Expansion in Vanta Bioscience Limited**

We are glad to inform that the National Good Laboratory Practice (GLP) re-certification audit has been successfully completed. The said re-certification audit also included scope expansion for Physical-chemical Testing (including five batch analysis). The scope of the said audit also included specific audit requests from USFDA & ECHA regulators.

The said re-certification granted by the NGCMA and shall be valid for a period of two years.

The management is of the opinion that the said expansion of scope in certification will open up substantial market for the Company and will also result in increase in the scope of work/studies being received from existing long term clients of the Company. The said scope in expansion request was long due owing to delay caused by COVID 19 pandemic and has now been successfully completed.

**Commencement of commercial operations in Vayam Research Solutions Limited ("Vayam")\***

The facility of Vayam Research Solutions Limited in Gandhinagar Gujarat is completed and having received DCGI approval for a period of 5 years, has been ready for commencing its operations.



**Research Center :**  
K2-B, 11<sup>th</sup> Cross Street, SIPCOT Industrial Complex,  
Gummidipoondi, Thiruvallur District, Tamilnadu - 601 201.  
Tel : 044 6790 1600

We are pleased to inform you that Vayam has started the first Pilot study from Emcure Pharmaceuticals, India. This Bio Equivalence is for a product intended to be submitted to the EU regulator (EMA) to be carried out in India and is a major milestone in the long-term association with Emcure Pharmaceuticals.

The promoters of the Company are not interested/related to the said order received.

*\*Vanta Clinical Research Limited ("VCRL") is a wholly owned subsidiary of Vanta Bioscience Limited and VCRL holds 36% in Vayam.*

Please note that the Trading Window for all designated persons as under Insider Trading Policy of the Company will be closed from July 29, 2021 till July 31, 2021.

This is for your information and for dissemination to the general public at large.

**For VANTA BIOSCIENCE LIMITED**



**ZOHEB SAYANI**

**COMPANY SECRETARY**

